These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 6437983)

  • 1. Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model.
    Wang LY; Frasch CE
    Infect Immun; 1984 Nov; 46(2):408-14. PubMed ID: 6437983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine.
    Frasch CE; Zahradnik JM; Wang LY; Mocca LF; Tsai CM
    J Infect Dis; 1988 Oct; 158(4):710-8. PubMed ID: 3139776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine.
    Rosenqvist E; Høiby EA; Bjune G; Aase A; Halstensen A; Lehmann AK; Paulssen J; Holst J; Michaelsen TE; Nøkleby H; Frøholm LO; Closs O
    Dev Biol Stand; 1998; 92():323-33. PubMed ID: 9554288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotype-specific monoclonal antibody.
    Brodeur BR; Larose Y; Tsang P; Hamel J; Ashton F; Ryan A
    Infect Immun; 1985 Nov; 50(2):510-6. PubMed ID: 3932211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appearance of new strains associated with group B meningococcal disease and their use for rapid vaccine development.
    Frasch CE; Mocca LF; Karpas AB
    Antonie Van Leeuwenhoek; 1987; 53(6):395-402. PubMed ID: 3130778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine.
    Beernink PT; Vianzon V; Lewis LA; Moe GR; Granoff DM
    mBio; 2019 Jun; 10(3):. PubMed ID: 31213564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 8. Protection against group B Neisseria meningitidis disease: effect of serogroup B polysaccharide and polymyxin B on immunogenicity of serotype protein preparations.
    Peppler MS; Frasch CE
    Infect Immun; 1982 Jul; 37(1):264-70. PubMed ID: 6809628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines.
    Zollinger WD; Moran EE; Devi SJ; Frasch CE
    Infect Immun; 1997 Mar; 65(3):1053-60. PubMed ID: 9038315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody studies in mice of outer membrane antigens for use in an improved meningococcal B and C vaccine.
    Milagres LG; Cristina M; Brandileone MC; Sacchi CT; Vieira VS; Zanella RC; Frasch CE
    FEMS Immunol Med Microbiol; 1996 Jan; 13(1):9-17. PubMed ID: 8821393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection.
    Rosenqvist E; Harthug S; Frøholm LO; Høiby EA; Bøvre K; Zollinger WD
    J Clin Microbiol; 1988 Aug; 26(8):1543-8. PubMed ID: 3139705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.
    Devi SJ; Zollinger WD; Snoy PJ; Tai JY; Costantini P; Norelli F; Rappuoli R; Frasch CE
    Infect Immun; 1997 Mar; 65(3):1045-52. PubMed ID: 9038314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic and protective properties of meningococcal serotype 2a protein in the hen-embryo model.
    Ashton FE; Ryan JA; Diena BB; Frasch CE
    J Med Microbiol; 1983 Nov; 16(4):443-57. PubMed ID: 6417339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens.
    Frasch CE; Peppler MS
    Infect Immun; 1982 Jul; 37(1):271-80. PubMed ID: 6809629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of meningococcal group B vaccine candidates: capsular or noncapsular?
    Diaz Romero J; Outschoorn IM
    Clin Microbiol Rev; 1994 Oct; 7(4):559-75. PubMed ID: 7834605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Status of a group B Neisseria meningitidis vaccine.
    Frasch CE
    Eur J Clin Microbiol; 1985 Dec; 4(6):533-6. PubMed ID: 3937731
    [No Abstract]   [Full Text] [Related]  

  • 17. Protection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia model.
    Craven DE; Frasch CE
    Infect Immun; 1979 Oct; 26(1):110-7. PubMed ID: 115794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease.
    Fischer M; Carlone GM; Holst J; Williams D; Stephens DS; Perkins BA
    Vaccine; 1999 May; 17(19):2377-83. PubMed ID: 10392619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine against meningococcal group B disease.
    Lifely MR; Moreno C
    Lancet; 1986 Jan; 1(8474):214-5. PubMed ID: 2868239
    [No Abstract]   [Full Text] [Related]  

  • 20. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.
    Frasch CE; Robbins JD
    J Exp Med; 1978 Mar; 147(3):629-44. PubMed ID: 416164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.